By administering iAluRil ® directly into the bladder, these components can help to repair the damage to the GAG layer and restore the bladder's protective coating, relieving these symptoms in some patients. GAG (glycosaminoglycan) layer: the barrier that protects the bladder lining from irritating and toxic substances found in urine. </span> role="button" aria-expanded="false">.
Objective: Bladder pain syndrome (BPS) is a chronic pain condition associated with injury to the glycosoaminoglycan (GAG) layer. We aimed to prospectively evaluate iAluRil® with multi-centre tertiary urogynaecology collaboration. We hypothesised that iAluRil® (a GAG therapy) would demonstrate equivalent symptom, pain and QOL scores compared to DMSO controls.
iAluRil®, listed as a medical device on the Australian Therapeutic Goods Registry (ATGR), contains both hyaluronic acid and chondroitin sulphate. This trial utilises iAluRil® for the same clinical indication as it is listed for on the ATGR, i.e. to re-establish the glycosaminoglycan (GAG) layers of the urothelial vesical tissue in cases in.
Unfortunately, choice of the dose and duration for oral treatment was purely empirical. Although the intravesical schedule was modulated in accordance with previous experience with intravesical HA/CS for the treatment of urinary tract infections or painful bladder syndrome, no evidence-based schedule exists for the dietary supplement.